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ABSTRACT
Background: Metabolic syndrome (MetS), a comprehensive condition is universally described as a group of several causative factors or abnormalities 
directly linked with insulin resistance that obviously augment the threat mainly for coronary heart disease, diabetes mellitus Type 2, some types 
of cancers and sleep disturbances, etc. MetS is a contemporary condition that covers a wide-ranging display of disorders with definite metabolic 
anomalies demonstrating at different times. Consequently, the threat of MetS remains epidemic. This review will potentially study significant 
factors such as central adiposity, insulin resistance, hypertension, and dyslipidemia; increased inflammation, environmental factors, and genetic 
predisposition are involved in MetS development.
Purpose: This review provides the available facts to validate the relationship between MetS and quality of life.
Methods: A thorough exploration in many search engines such as PubMed, Medline, Science direct, EMBASE, and Google scholar was carried out to 
recognize qualified studies.
Results: Almost all studies suggested that MetS is significantly associated with impair quality of life. Lifestyle intervention holds the early preference 
and such non-pharmacological therapy combines specific suggestion on diet and physical activity with behavioral strategies. For the individuals, 
where contributing factors are not sufficiently condensed with lifestyle changes, pharmacological treatment should be considered.
Conclusion: Therefore, the current study reviews the outline of literature interrelated with the MetS’s characterization, epidemiological existence, 
pathological process, and management advance for all the risk factors encompassing metabolic disorder.
Keywords: Cardiovascular disorders, Inflammation, Insulin resistance, Metabolic syndrome, Obesity, Occurrence.
INTRODUCTION
In the recent past years, an authentic torrent of research has been 
observed regarding a new problem-solving category: The metabolic 
syndrome (MetS) [1]. It is a chronic provocative outbreak highly 
contributing mainly to cardiovascular mortality [2]. The definition, 
conditions, and management choices are now strongly debated. 
Consequently, the threat of MetS can be truly considered an 
epidemic [3,4]. MetS, rise up the health-care cost, which becomes a 
significant burden to the developed and developing countries all over 
the world. MetS instigation is recognized to a degree of inherited 
tendency formed by several genes united with an inactive routine 
and a diet including surfeit calories. Detection of patients among 
characteristics of this condition and suitable management is essential to 
diminish the undesirable consequences on health linked with MetS [5]. 
The major intention of this review is to put in forth various facets of 
MetS of shedding some radiance on the particular condition.
DEFINITIONS AND THE DIAGNOSTIC CRITERIA OF METS
The MetS encompasses the grouping of interrelated cardiovascular risk 
factors, together with central obesity, hypertension, dyslipidemia, and 
also hyperglycemia and is extensively established that it is budding 
and emerging global issue. It is a chief and intensifying communal 
health challenge globally due to the urbanization development, excess 
energy intake, cumulative obesity, and also lethargic lifestyle. Prior 
identification or prognosis is a key to utilize effectively lifestyle and 
risk factor adaptation. Since then, the perception of MetS has gradually 
emerged into medical practice, and quite a few definitions have been 
projected to portray MetS as considered in more detail later [6,7].
Recently, numerous functioning definitions have been prepared for 
the MetS. The MetS syndrome is generally categorized by central 
abdominal obesity, dyslipidemia, amplified blood pressure (BP), 
glucose intolerance, and insulin resistance [9-12]. In the year 1998, the 
WHO initiated a definition for the MetS [1], and later it was modified in 
the year 1999 [9]. By the year 1999, even the European group for the 
study of insulin resistance organized their definition [10], whereas by 
2001, the National Cholesterol Education Program’s Adult Treatment 
Panel III (ATP III) [11], adapted by an American Heart Association, 
2005 [3] and also the International Diabetes Federation in 2005 [12].
EPIDEMIOLOGY
The MetS started as awareness rather than a diagnosis. In 1920, Mets 
instigated with the association of elevated BP, hyperglycemia, and gout. 
Then, late in the 1940’s, the abdominal obesity was also commonly 
linked with the metabolic abnormalities. Later, it was described that 
the etiology of the MetS remains versatile; regarded as a cluster of 
risk factors for diabetes and cardiovascular disease (CVD). Many 
have struggled to progress diagnostic criteria for the identification of 
the MetS [13-15]. Millions of people all through the world have been 
diagnosed with MetS [16]. Mostly European countries and in the 
western nations the commonness of the MetS has reached almost one-
third of the total population, and the occurrence is still advanced in the 
age groups [17,18]. The prevalence of the MetS is increasing all over the 
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world due to the worldwide increase in central adiposity and inactive 
lifestyles [19]. Nearly, the MetS has spread its condition on one-fourth 
population of North Americans [20]. Akin, occurrence in MetS has been 
observed in Scandinavian populations [21]. According to the NHANES 
study, the frequency of the MetS in the western countries increased 
in middle-aged populations. MetS has become further rampant with 
escalating age paralleled by an increase in age-associated diseases and 
anomalies [22] Fig. 1.
The incidence of MetS ranges from <10% to 84%. Number of factors 
may be involved in the incidence of MetS, pertaining to the province, 
metropolitan or rural setting, gender, age, ethnicity, gut microbiota, 
food patterns, and the culture of the population studied. Furthermore, 
sex-related variations in MetS predominance all through the world are 
not constant. These dissimilarities may be due to cultural diversity 
and diversified waist circumference used in altered populations [23]. 
Sophisticated socioeconomic status, inactive lifestyle, and an increased 
BMI (Body Mass Index) were considerably connected to MetS [24]. 
A study detected that there is a steady elevation found in the incidence 
of MetS since two decades all through their 60s and 70s [25]. 
Consequently, this global health issue needs to be addressed; hence, 
preventive health procedures should be carried out.
The schematic representations of the MetS are as follows Fig. 2:
ETIOPATHOGENESIS
The mechanisms involved in the pathogenesis of MetS are so 
intricate that requires a complete elucidation. Although MetS varies 
in distribution; recently, it has distributed even in the developing 
countries which accentuate the significance of environmental and 
routine life aspects such as the burning up of additional calories along 
with the deficit of physical activity as being chief contributors [26.]
MetS is characterized by prolonged low-grade inflammatory condition 
emerging with adipose tissue and, in addition, involves immune cells, 
as a result, discharges inflammatory substances such as cytokines. 
Furthermore, it leads to endothelial dysfunction which may cause an 
increased risk of atherothrombosis, hypertension, and CVD. Although 
the pathogenesis of the MetS and each of the mechanism is complex, 
insulin resistance, abdominal adiposity, atherogenic dyslipidemia, 
hypertension, persistent stress, and chronic inflammation remain the 
most significant risk factors of the syndrome [27] Fig. 3.
Insulin resistance
Hyperinsulinemia coupled with insulin resistance seems to be an essential 
factor involved in the pathogenesis of the MetS. Augmented free fatty acids 
(FFAs), which are circulating due to insulin resistance-mediated, are thought 
to enact a key role in the development of MetS. In adipose tissue, inhibition of 
lipolysis mediated by insulin resistance, thus leading to in rise in circulating 
FFAs. These further prevent the protein kinase. FFAs hinder protein kinase 
stimulation in the muscle proceeding with decreased glucose uptake [28].
In the presence of the MetS, insulin has a selective dysfunction so that 
it does not diminish the hepatic glucose output, but rather increases it, 
and further causing dyslipidemia [29]. Insulin resistance also causes an 
increase in serum consistency, augmented conversion of prothrombin to 
thrombin, and ultimately the discharge of inflammatory substances like 
cytokines from the fat cell which facilitates amplified risk of CVD [30].
Another factor that contributed to the development of the MetS is an 
excessive nutrient intake which can alter the mitochondrial function 
leading to defective insulin secretion and Type II diabetes mellitus [31]. 
Furthermore, disproportionate nutrient intake can result in obesity, as 
visceral fat. Insulin resistance is more developed visceral fat deposition 
rather than subcutaneous deposition which directed to a better supply 
of FFAs that cause an increased triglyceride synthesis. This altered 
lipid metabolism which occurred in the liver ends up causing in the 
rise in low-density lipoprotein cholesterol (LDL-C) and diminished 
high-density lipoprotein cholesterol (HDL-C) levels [32].Fig. 1: The diagnostic criteria for metabolic syndrome
Fig. 2: Schematic representation of metabolic syndrome
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The inherited fat predominantly secretes the inflammatory cytokines 
tumor necrosis factor- α (TNF-α) and interleukin 6 (IL6). The 
production of cytokines causes an increase in lipolysis and results 
in hypertriglyceridemia [33]. Consequently, this visceral fat will 
be coupled with metabolic alterations. A genetic susceptibility for 
both central adiposity and the expansion of the MetS is probably an 
underlying cause of the development [34].
Abdominal obesity as the driving force
In many areas of the world, rising incidence of adiposity is the main dynamic 
force following the high commonness of the MetS. The problem of central 
obesity is also seen equally in young people, as well as in the elderly. In 
regard to the metabolic anomalies that cause the risk for cardiovascular and 
other ailments, waist circumference measurement may prove to be the sole 
indicator [35]. Although fat deposits regarded, as an unreceptive storage 
site for energy that may possibly be use in the moment that we need [36].
Adipose tissue along with its related deformities can influence to cause 
insulin resistance due to alterations in the FFA levels within cells. These 
effects of insulin resistance can cause interrelated changes leading to 
oxidation of fatty acid thereby causing an alteration in the endothelial 
function [37].
Even, an association exists between a prior recognizable history of 
obesity and MetS development was identified. Numerous studies 
have shown that genetic background could manipulate MetS origin. 
The genetic constitution of an individual with leptin polymorphisms 
was also linked with metabolic abnormalities, thus proved to contain 
elevated concentration of leptin. Yet, it has been shown that alteration 
in the growth of microorganisms could progress MetS. Another study 
reported that MetS risk factor includes the measurement of depression. 
The crucial reason for the MetS genesis is the environmental factor. 
Other report exhibited a correlation between MetS and consumption 
of excessive food. And also, a study [38] reported that the consequence 
of a high sugar diet causes an augmented oxidative stress which leads 
to deterioration in the cardiovascular function and eliminate female 
defense again cardiovascular dysfunction. Furthermore, in elderly 
obese patients, MetS has been related to abdominal obesity and 
inflammation at advanced levels, measured by IL-6 (ILs), TNF-α, and 
PAI-1 [39]. Moreover, adiposity is regarded as the type of obesity mainly 
tied with MetS and determined as the predictable causative factor for 
the diagnosis of the syndrome [40].
In addition, numerous drugs, such as corticosteroids, antipsychotics, 
antidepressants, and antihistamines can influence MetS characteristics 
including adiposity and glucose intolerance [41].
Neurohormonal activation
Stimulation of the renin-angiotensin system also provides a significant 
neurohumoral pathway contributing further mechanistic insights 
into the advancement of metabolic abnormalities. As a consequence 
of Angiotensin-converting enzyme stimulation, angiotensin-II, as well 
it is synthesized by adipose tissue [42]. Through activation of the 
angiotensin receptor (AT-1), proceeds to the generation of reactive 
oxygen species (ROS) [43] which produces major result proceeding 
with LDL-oxidation, endothelial dysfunction, aggregation of platelets, 
and generation of lectin-like oxidized LDL receptor-1 (LOX-1) [44]. Such 
process initiates inflammation, endothelial injury, and proliferation of 
cells that contribute to the advancement of BP, high lipid levels, blood 
sugar, cardiac dystrophy, and CVD [45].
Hypertension
Numerous metabolic abnormalities as shown in Fig. 4, mainly central 
adiposity, and increased blood sugar level are the main causes of 
essential hypertension. Studies suggest that insulin resistance and 
hyperinsulinemia leads to the stimulation of sympathetic system, and, 
consequently, the renal system enhance sodium reabsorption, the heart 
shows increased cardiac output, and also increased arterial pressure 
causes vasoconstriction ensuing in hypertension. In a study, it was 
shown that the MetS was present in a high proportion of the sample of 
patients with hypertension [46,47].
Inflammation
Inflammation plays an important part in the development of 
cardiovascular disease and proved by the presence of inflammatory 
markers seen elevated in patients with MetS [48]. Macrophages present 
inside the fat cells produce TNF-α, and its synthesis enhances with an 
elevation in the weight of adipose tissue. This production of TNF-α 
leads to the inactivation of tyrosine kinase receptors, the increasing FFA 
due to lipolysis and inhibition of adiponectin discharge are normally 
caused by TNF-α stores in the adipose tissue [49]. Therefore, prominent 
serums levels of TNF-α are related with central adiposity and glucose 
intolerance, as these are the chief elements of MetS [50].
Adipocytes and immune cells have complex regulatory mechanisms 
to produce IL-6 [51]. However, synthesis of IL-6 enhances with raise in 








Fig. 4: Pathogenesis of hypertension in the metabolic syndrome. 
*Renin angiotensin aldosterone system. #Somatic nervous system
7
Asian J Pharm Clin Res, Vol 11, Special Issue 4, 2018, 4-11
 Rajalakshimi and Aanandhi 
adiposity and insulin resistance. This formed cytokine works on the 
hepatocytes, bone marrow, and vascular endothelium, thus causing an 
augmented production of reactive proteins. Quite number of researches 
has established a relationship amidst elevated C reactive protein levels 
and the advancement of MetS [53]. IL-6 also enhances fibrin levels ensuing 
state of coagulation and advances expression of endothelial cells [54].
Dyslipidemia
It is characterized by a range of lipid level deformities that affect in 
the composition, metabolism, and inherited activities of lipoproteins 
that comprises an increase in lipoproteins, increased triglycerides 
(TG), enhanced LDL-C levels, and suppressed HDL-C levels. Insulin 
resistance directed to cause irregular levels in cholesterol in several 
ways. In general insulin usually diminishes breakdown of lipids in 
adipocytes, ensuing in increased FFA levels. Furthermore, results in 
augment production of very LDL (VLDL) and thus causes a reduction in 
VLDL clearance by enhancing an atheroma formation [54]. Thereby, it 
is understood that the augmented VLDL secretion causes dyslipidemia 
associated with insulin resistance [55].
Inheritance
An immense difference in the susceptibility and age, propose a 
major relation exist between genetic and environmental factors [56]. 
Elevated plasma glucose to unusual levels is chiefly caused by genetic 
predisposition to the insulin secretion when shared with insulin 
resistance. The metabolic alterations are advantageous for those 
subjects who are poorly nourished all through the earlier and later life; 
conversely, by means of improved calorie consumption, these variations 
are no more favorable and probably may direct to an augmented threat 
of MetS in a future part of life [57].
Endothelium dysfunction
A study by Hansson has shown that a diminution in nitric oxide, regarded 
as a vital monitor of endothelial function and a rise in ROS ends up in 
endothelial dysfunction. Thus, vasodilatation impairment decreased 
arterial acquiescence, and accelerated development of atherosclerosis 
can be prognostic factor to MetS [58]. An incapability of endothelium 
to provide its usual physiological and defensive mechanisms involves 
numerous factors such as oxidative stress, elevated blood glucose 
levels, complex glycation products, FFAs, cytokines, or adipokines [59].
Role of cortisol
Genetic predisposition in individuals, due to chronic hypercortisolism 
results in hypersecretion of cortisol, a hormone secreted during stress 
which perhaps accumulates fat deposition in the adipose tissue [60]. 
Cortisol increases the enzymatic activation concerned in the synthesis 
of fatty acid and thereby advancing the discharge of LDL and TG; 
provoking the liver for the gluconeogenesis; reduced uptake of amino 
acids and increased addition of oxygen to the lipids causes resistance 
to the insulin secretion [61]. Strong association was identified amidst 
the levels of cortisol, and the amount of characteristics of the MetS 
when studied on subjects; thus, hormonal alterations may lead to 
dyslipidemia, hypertension, and type 2 diabetes mellitus (T2DM) [62].
CLINICAL MANIFESTATIONS OF METS
MetS entails an augmented risk for mortality from CVD and also from 
increase in diabetes mellitus. The two components of MetS - Type 2 
diabetes mellitus and coronary heart disease (CHD) - have acquired 
epidemic proportions globally. The escalating inhabitants of overweight 
and obese individuals constrain this rising threat. Even children with 
obesity are also at an increased risk of adolescent and adult obesity [63], 
which again enhances the threat of cardiovascular disease in later life. 
MetS is further related to many disorders polycystic ovary syndrome, 
obstructive sleep apnea, hypogonadism, and some forms of cancer [64].
Quality of life is much deteriorated in MetS patients, as there is a 
complete sluggish physical routine that affects the normal actions of 
patients [65]. Chronic MetS prevalence might show conclusive effects 
on physical comorbidities as observed in Fig. 5.
Cardiovascular disease
The complication of MetS which includes CHD, myocardial infarction 
and also stroke be the principal reason behind the increased mortality 
rate in developed countries. A study by Mottillo et al. [67] exhibited that 
patients with MetS are more prone to develop T2DM and clinical CVD. 
Such study was also supported by another finding by Wilson et al. [68] 
that increased risk of CVD events exists in case of MetS. Furthermore, 
findings suggested that atherosclerosis and the threat of CVD rise with 
all the risk factors involved as MetS components [66,69].
Type II diabetes
Type II diabetes is illustrated by decreased insulin production and 
insulin resistance. Most of the diabetic patients, who are obese, maybe 
perhaps reported with deficiency of insulin or its resistance. Chronic 
hyperglycemia and increased FFA levels resulting from lipolysis can 
inhibit the gene expression of insulin and as a result damage glucose-
dependent insulin production [70]. As a known fact that insulin 
stimulates uptake of glucose predominantly in fat cells, muscle build 
and in the hepatocytes. Insulin defiant would be an indicator for 
measuring people with MetS. Consequently, further insulin is necessary 
to activate the insulin-mediated glucose uptake by cells. Hyperglycemia, 
a causative factor for a diabetic which includes damage of retina, 
chronic loss of kidney function, dysfunction of peripheral nerves and 
angioplasty, linked with both decreased in the average lifespan of an 
individual, and considerable deterioration in the standard of health. 
MetS being a predecessor of Type 2 diabetes, the patients might have 
increased risk of CVD comorbidities [18,71].
Even after the progression of insulin resistance and metabolic 
anomalies, medical expression of the disease may not be present over 
some years. Before the development of T2DM disease, the advancement 
of macrovascular and microvascular disease is progressed [71]. The 
guidelines from NCEP ATP III illustrate that T2DM is an equivalent risk 
as CHD. Patients with diabetes and clinical atherosclerotic disease must 
take aggressive preventive measures [72].
Steatohepatitis
The most common causes of liver disease in adults are steatohepatitis 
(fatty liver). Fatty liver disease distinguished by liver injury and 
deposition of fat in the liver (<5% liver weight) [73]. Fatty liver further 
may lead to cirrhosis and liver failure. Damage of liver is also related 
with resistance to insulin, categorized by damaged ability of insulin 
to decrease the production of glucose from the liver. Consequently, 
resulting in mild decrease in sugar level and increased in insulin 
secretion, proceeding with hyperinsulinemia [74]. Thus, deposition 
of fat in liver is related with the mechanisms of the MetS. Rise in the 
occurrence of non-alcoholic fatty liver disease is accompanied with an 
epidemic of MetS. The relationship between MetS and steatohepatitis 
recommends that they may possibly share a mutual physiologic 
predecessor [75]. This association has led to the concern to observe its 
role in the development of CVD [76].
Cancer
The advanced risk in the colon or rectal cancer is allied with the 
magnitudes of adiposity and resistance to insulin in case MetS condition. 
Fig. 5: Clinical implications of the metabolic syndrome
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Further a study by Harding et al. [65] found that those subjects with 
MetS components exhibit an augmented risk for colon or rectal cancer. 
Similar studies exhibited a possible connection that exists between 
breast cancer and MetS and also established that MetS amplifies the risk 
of breast cancer mortality [65,78]. There is a high susceptibility of MetS 
components to cause the evolution of tumor. Therefore, it is mandatory 
to differentiate the possible interlinks between these components and 
its risk [79].
Other manifestations
MetS is usually related with a disorder of the gastrointestinal tract, 
and also a study reported the fact that irritable bowel syndrome is 
present in most of MetS subjects. A study conducted by Chang et al., 
demonstrated that advanced pervasiveness of MetS was reported in 
adults with Helicobacter pylori infection [80].
Sleep apnea and polycystic ovarian syndrome (PCOS) are the other 
manifestations of MetS. MetS arise repeatedly in patients with 
obstructive sleep apnea due to obesity. Advanced incidence of 
cardiovascular morbidity and mortality is observed in patients with 
obstructive sleep apnea [81]. The incidence of MetS may probably 
explain the association between them [82]. Though PCOS, regarded as 
by ovulation, excess of androgen and glucose intolerance, the etiology 
of this syndrome remains unclear [83,84]. The pathogenic role in the 
progression of PCOS includes resistance to the insulin characterized 
by hyperinsulinemia [85]. Women with polycystic ovary syndrome are 
more prone to MetS; consequently, they are more susceptible to CVD. 
It is also described in a study where nearly half (46.4%) of the women 
suffering with PCOS had MetS [83].
A true fact is observed in a study where Mets has been associated with 
beginning of chronic kidney disease [86]. Subsequent to percutaneous 
nephrolithotomy, a minimal invasive procedure to remove stones from 
the kidney, a study demonstrated that stone return rates and kidney 
damage were high as a consequence of MetS [87].
In recent times, it was observed that the group of mental disorders is in 
association with MetS prevalence [88]. A study reported that it is very 
common to be affected by bipolar disorder if the patients were already 
suffering from MetS. Furthermore, molecular level modifications 
observed in MetS including endothelial dysfunction can be bought in 
association with much type of central nervous system disorders such as 
anxiety, loss of memory, depression, and stroke [89].
Since cytokines and adipocytokines involvement and accountability 
are high in MetS, it could be easily associated with skin disease such as 
psoriasis [90].
MANAGEMENT OF THE METS
MetS can be easily managed by approaching through a dual point of 
view that unites non-pharmacological treatment and pharmacological 
considerations in an attempt to reduce many clinical conditions. To 
reduce the risk of many other diseases, prognosis and management 
become an essential part [91]. The implementation can be initiated with 
lifestyle changes, diet, weight loss, and exercise, which accounts for the 
non-pharmacological therapy. Nevertheless, if the MetS patients are not 
adequately responded with the preventive measures as mentioned use 
of drugs can be considered [92].
Healthy diet
Eating habits or the dietary pattern had become the major concern 
for the patients suffering from MetS. Proper care in healthy eating 
habits should produce a significant difference in MetS prevention. It 
is so common after the globalization, which processed foods are on 
garage trade extensively. MetS is more prone to, as there is excessive 
consumption of these calorie-rich foods. Dietary patterns that include 
elevated intakes of fresh fruits, greens, vegetables, fish, nuts, and cereals 
are proportionally associated with MetS mitigation. Research facts 
expose that the healthy diet can avert the MetS. Schools, universities, 
and social media should publicize healthy eating habits that include 
a sufficient consumption of good fats (monosaturated) and proteins 
among population worldwide. And also, the promotion of education 
about health on eating habits and their choices over food should be 
considered through pamphlets or community awareness. Every nation 
has their nutritional prototypes for the good choices of health and 
thereby attempting to avoid the MetS [93-95].
Low sodium ingestion provides a better effort to regularize the BP in 
patients suffering with MetS. Even in another study, it was reported that 
BP becomes very high in salt ingestions observed in case of MetS [96]. 
Similar study [97] evaluated during 1 year on male patients suffering 
from MetS, showed that the physical activity and healthy diet patterns 
had reduced the MetS incidence to almost 32.6%. Less commonness of 
MetS is observed with populations sticking on to the Mediterranean 
diet. Moreover, such diet includes consumption of reduced carbohydrate 
and more monounsaturated fats that might prove to improvise MetS, 
especially by lowering the lipid levels, increasing the insulin action, 
and augmented performance of the liver. Moreover, to prevent MetS, all 
healthy diets should be promoted worldwide. And also, adaptation in 
an improvised food habits can advance the MetS occurrence at an early 
age and hence can revert its complication [93-95].
Lifestyle modification
Lifestyle adaptation method and some important views on health 
education should be shared by a team comprised all health-care 
professionals. Although there is a complete acceptance that these 
lifestyle behaviors such as weight loss and healthy dietary patterns are 
the first-line therapy to avoid the occurrence of MetS, the ultimate diet 
pattern and type of exercise remains vague [98-100].
Weight loss, insulin sensitivity, insulin action in muscles, elevation of 
HDL cholesterol levels, reduction in triglyceride levels, and decreased 
hypertension might result from an adequate amount of physical 
involvement through exercise. Through their actions on individual 
components such as obesity, waist circumference, and insulin resistance 
any form of physical exercise might defend against the progression 
of MetS [101,102]. Even studies have reported that there is a strong 
influence between the reduced levels of inflammatory mediators such 
as cytokines with increased physical activity [103]. In a 4 years follow-
up study, as compared to the men whose physical activity is very less, 
men involving a reasonable or forceful physical activity were less prone 
to MetS [104]. Further, it is yet uncertain whether exercise only can 
decrease the risk of developing the MetS without the support of weight 
loss [100].
Bariatric surgery
Bariatric surgery is recommended especially for severe obesity and 
also for those subjects who have shown null response to the weight 
loss schemes. Due to the redistribution of fat, improvements in the lipid 
and biochemical report have been recognized [16]. A technique where 
a gastric bypass is made, and thus it has been found to improve other 
disorders such as diabetes, adiposity, elevated BP, steatohepatitis, CVD, 
dyslipidemia, and infertility [105]. Proper management is requiredas 
the long-term results remain uncertain and only very minimal safety is 
observed on geriatric patients.
Pharmacotherapy
Pharmacotherapy remains the next option to lifestyle modification. Long-
lasting use of several medications (polypharmacy) is preferred over 
specific drug prescribed as the present strategy of pharmacotherapy yet 
results in poor compliance [7]. Mostly the treatment involves lipid level 
management using statins, insulin expression or its sensitivity can be 
improvised by anti-diabetic drugs, hence reducing the risk of diabetes 
and deteriorating risk of clotting that inhibits the platelet aggregation. 
In addition, in an attempt to reduce the risk and development of MetS; 
nowadays, interest has also been turned toward the utilization of 
natural plant products their action on prolonged term remains unclear 
in regards to cardiovascular outcomes and compliance [8]. And also, a 
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multifaceted approach to MetS can be considered as in Table 2.
Management of MetS through drugs is suggested over lifestyle measures 
in patients with cardiovascular comorbidities to reach the targeted goals 
for reducing the lipoprotein levels and to regulate hypertension [25]. 
Drug classification for the treatment of MetS comprises of statins, 
fibrates, and angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers [24]. The underlying conditions that advance the 
development of MetS and diabetes mellitus are obesity, physical 
inactivity, and diet; therefore, lifestyle modifications are the first step 
for the prevention of it. Hence, to avert and diminish the advancement 
of MetS as well, the cardiovascular mortalities earlier prognosis and 
management remains crucial [53].
CONCLUSION
MetS has an augmented risk of diabetes mellitus and cardiovascular 
disorder. The incidence of numerous causative factors demands 
multifactorial management that encompasses glycemic control, lipid-
lowering therapy, BP regulation, and antiplatelet treatment. Non-
pharmacological therapy such as lifestyle interventions being the 
preliminary preference that usually determines a strategy that works 
with particular dietary patterns and regular physical activity. Healthy 
diet patterns that include elevated intakes of fresh fruits, greens, 
vegetables, fish, nuts, and cereals are proportionally associated with 
MetS mitigation. Although MetS prevalence remains globally, it is 
developed through numerous factors such as food choices, exercise, 
innate genetic influence, status, gender, living era, nd educational 
occupation. To elucidate the origin, a mandatory step must be taken 
to focus on these components. Mostly, the quality of life of these MetS 
patients may be perhaps affected due to their sedentary behavior. 
Management of MetS includes treatment such as scheduled exercise, 
list of pharmacologically classified drugs or even the interventional 
procedures. This review presently demonstrated that increased 
physical activity has distinguished importance in MetS avoidance and 
revival; mainly food choices with regular diet are proportionately 
linked with MetS improvement. Further research will be explored to 
encourage the clinical diagnosis and also must depict the true impact 
of effective management of all elements pertaining to this syndrome.
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